Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Efficient high throughput SARS-CoV-2 testing to detect asymptomatic carriers

View ORCID ProfileNoam Shental, Shlomia Levy, Vered Wuvshet, Shosh Skorniakov, Yonat Shemer-Avni, Angel Porgador, View ORCID ProfileTomer Hertz
doi: https://doi.org/10.1101/2020.04.14.20064618
Noam Shental
1Department of computer science, Open University of Israel
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Noam Shental
  • For correspondence: thertz@bgu.ac.il angel@bgu.ac.il noam@openu.ac.il
Shlomia Levy
2Department of Microbiology and Immunology, Ben-Gurion University of the Negev
3National Institute of Biotechnology in the Negev, Ben-Gurion University of the Negev
BSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vered Wuvshet
2Department of Microbiology and Immunology, Ben-Gurion University of the Negev
3National Institute of Biotechnology in the Negev, Ben-Gurion University of the Negev
BSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shosh Skorniakov
2Department of Microbiology and Immunology, Ben-Gurion University of the Negev
3National Institute of Biotechnology in the Negev, Ben-Gurion University of the Negev
MSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yonat Shemer-Avni
2Department of Microbiology and Immunology, Ben-Gurion University of the Negev
4Soroka University Medical Center, Beer-Sheva, Israel
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Angel Porgador
2Department of Microbiology and Immunology, Ben-Gurion University of the Negev
3National Institute of Biotechnology in the Negev, Ben-Gurion University of the Negev
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: thertz@bgu.ac.il angel@bgu.ac.il noam@openu.ac.il
Tomer Hertz
2Department of Microbiology and Immunology, Ben-Gurion University of the Negev
3National Institute of Biotechnology in the Negev, Ben-Gurion University of the Negev
5Vaccine and Infectious Disease Division, Fred Hutch Cancer Research Center
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Tomer Hertz
  • For correspondence: thertz@bgu.ac.il angel@bgu.ac.il noam@openu.ac.il
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

The COVID-19 pandemic is rapidly spreading throughout the world. Recent reports suggest that 10-30% of SARS-CoV-2 infected patients are asymptomatic. Other studies report that some subjects have significant viral shedding prior to symptom onset. Since both asymptomatic and pre-symptomatic subjects can spread the disease, identifying such individuals is critical for effective control of the SARS-CoV-2 pandemic. Therefore, there is an urgent need to increase diagnostic testing capabilities in order to also screen asymptomatic carriers. In fact, such tests will be routinely required until a vaccine is developed. Yet, a major bottleneck of managing the COVID-19 pandemic in many countries is diagnostic testing, due to limited laboratory capabilities as well as limited access to genome-extraction and Polymerase Chain Reaction (PCR) reagents. We developed P-BEST - a method for Pooling-Based Efficient SARS-CoV-2 Testing, using a non-adaptive group-testing approach, which significantly reduces the number of tests required to identify all positive subjects within a large set of samples. Instead of testing each sample separately, samples are pooled into groups and each pool is tested for SARS-CoV-2 using the standard clinically approved PCR-based diagnostic assay. Each sample is part of multiple pools, using a combinatorial pooling strategy based on compressed sensing designed for maximizing the ability to identify all positive individuals. We evaluated P-BEST using leftover samples that were previously clinically tested for COVID-19. In our current proof-of-concept study we pooled 384 patient samples into 48 pools providing an 8-fold increase in testing efficiency. Five sets of 384 samples, containing 1-5 positive carriers were screened and all positive carriers in each set were correctly identified. P-BEST provides an efficient and easy-to-implement solution for increasing testing capacity that will work with any clinically approved genome-extraction and PCR-based diagnostic methodologies.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

no external funding was used for this study

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

all code is publicly available on github

https://github.com/NoamShental/PBEST

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted April 20, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Efficient high throughput SARS-CoV-2 testing to detect asymptomatic carriers
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Efficient high throughput SARS-CoV-2 testing to detect asymptomatic carriers
Noam Shental, Shlomia Levy, Vered Wuvshet, Shosh Skorniakov, Yonat Shemer-Avni, Angel Porgador, Tomer Hertz
medRxiv 2020.04.14.20064618; doi: https://doi.org/10.1101/2020.04.14.20064618
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Efficient high throughput SARS-CoV-2 testing to detect asymptomatic carriers
Noam Shental, Shlomia Levy, Vered Wuvshet, Shosh Skorniakov, Yonat Shemer-Avni, Angel Porgador, Tomer Hertz
medRxiv 2020.04.14.20064618; doi: https://doi.org/10.1101/2020.04.14.20064618

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (280)
  • Allergy and Immunology (579)
  • Anesthesia (140)
  • Cardiovascular Medicine (1947)
  • Dentistry and Oral Medicine (252)
  • Dermatology (184)
  • Emergency Medicine (333)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (699)
  • Epidemiology (11102)
  • Forensic Medicine (8)
  • Gastroenterology (624)
  • Genetic and Genomic Medicine (3170)
  • Geriatric Medicine (309)
  • Health Economics (561)
  • Health Informatics (2042)
  • Health Policy (863)
  • Health Systems and Quality Improvement (782)
  • Hematology (310)
  • HIV/AIDS (682)
  • Infectious Diseases (except HIV/AIDS) (12721)
  • Intensive Care and Critical Care Medicine (707)
  • Medical Education (317)
  • Medical Ethics (92)
  • Nephrology (334)
  • Neurology (2986)
  • Nursing (164)
  • Nutrition (464)
  • Obstetrics and Gynecology (589)
  • Occupational and Environmental Health (614)
  • Oncology (1552)
  • Ophthalmology (478)
  • Orthopedics (185)
  • Otolaryngology (266)
  • Pain Medicine (202)
  • Palliative Medicine (57)
  • Pathology (403)
  • Pediatrics (913)
  • Pharmacology and Therapeutics (382)
  • Primary Care Research (355)
  • Psychiatry and Clinical Psychology (2785)
  • Public and Global Health (5591)
  • Radiology and Imaging (1094)
  • Rehabilitation Medicine and Physical Therapy (635)
  • Respiratory Medicine (760)
  • Rheumatology (339)
  • Sexual and Reproductive Health (311)
  • Sports Medicine (289)
  • Surgery (343)
  • Toxicology (48)
  • Transplantation (159)
  • Urology (132)